16 citations
,
April 2020 in “JAMA dermatology” More inflammation leads to faster and worse hair loss in women with frontal fibrosing alopecia.
37 citations
,
April 2019 in “Journal of The American Academy of Dermatology” This review assessed the effectiveness of various treatments for frontal fibrosing alopecia and found that intralesional steroids and 5α-reductase inhibitors showed the most positive outcomes in slowing or halting hair loss, though the lack of placebo-controlled studies and consistent outcome measures limits definitive conclusions.
14 citations
,
April 2019 in “International Journal of Women's Health” This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.
61 citations
,
January 2019 in “American Journal of Clinical Dermatology” This review discusses the potential causes and treatments for frontal fibrosing alopecia but reports no new clinical findings, highlighting the need for further research to understand its pathogenesis and develop validated treatments.
4 citations
,
January 2019 in “Dermatology Online Journal” This article discusses the potential of low-dose naltrexone as an adjuvant therapy for trichodynia in alopecias, noting its anti-inflammatory properties and need for further research.
8 citations
,
October 2018 in “Journal of The American Academy of Dermatology” This study evaluated treatments for frontal fibrosing alopecia and found hydroxychloroquine and 5a-reductase inhibitors to be most effective, with 70-72% of patients experiencing stabilization or improvement, but limitations in treatment consistency and assessment methods remain.
36 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.
8 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This correspondence discusses the diagnostic criteria for frontal fibrosing alopecia but reports no new research findings, agreeing with many previously suggested criteria.
30 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This correspondence discusses proposed updates to the diagnostic criteria for frontal fibrosing alopecia, emphasizing the importance of differentiating it from other types of alopecia.
39 citations
,
November 2017 in “PubMed” This case series reported that low-dose naltrexone may benefit patients with lichen planopilaris by reducing scalp symptoms and slowing disease progression, with no adverse effects observed in the patients.
95 citations
,
November 2016 in “Journal of The American Academy of Dermatology” This article reviews primary cicatricial alopecias, focusing on lymphocytic forms such as chronic cutaneous lupus erythematosus, according to a classification by the North American Hair Research Society, and reports no new clinical results.
40 citations
,
January 2013 in “International journal of trichology” This study found that among women with frontal fibrosing alopecia, 100% showed dermoscopic elements suggestive of the condition, with perifollicular erythema often indicating disease activity.
23 citations
,
January 2010 in “Journal of The American Academy of Dermatology” This article discusses the efficacy and safety of mycophenolate mofetil and hydroxychloroquine for treating lichen planopilaris and reports no new clinical results.
